Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
NanoVibronix Inc., now ENvue Medical Inc., reports medical-technology developments centered on enteral access, non-invasive therapy and commercialization under the FEED ticker following its completed name and symbol change from NAOV. The company’s ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for assisting clinicians with feeding-tube placement in the gastrointestinal tract, with FDA 510(k) clearance for adult use and real-time bedside visualization.
Recurring updates include ENFit syringe launches and distribution, UroShield® reimbursement and market-access developments, patent activity for feeding-tube navigation and visualization, and commercial leadership changes. The company also describes acoustic-based therapeutic technologies, including PainShield® and UroShield®, that use proprietary low-intensity surface acoustic wave technology for pain, bacterial colonization and biofilm-related applications.
ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for Application No. 18/199,059 titled "Feeding Tube with Electromagnetic Sensor and Camera" on Feb 24, 2026. The allowed patent includes 18 claims combining distal-tip camera imaging, embedded electromagnetic sensing, and MRI safety design elements.
ENvue says the invention aims to enable real-time visualization plus continuous positional tracking to improve placement confidence and support future product development of the ENvue Navigation Platform.
ENvue Medical (NASDAQ: FEED) signed a nationwide distribution agreement with U-Deliver to supply its recently launched over-the-counter reusable ENFit Syringe line through non-acute channels. The syringes are available OTC via U-Deliver website, Amazon storefront, and wholesale in 2.5, 5, 10 and 60 mL sizes.
The ENFit syringes meet ISO 80369-3 standards and are designed for reuse up to seven days or 20 uses, aimed at improving enteral care access in home and long-term care settings.
ENvue Medical (NASDAQ: FEED; NASDAQ: NAOV) announced on January 21, 2026 the appointment of Marc Waldman as Vice President, Commercial to lead U.S. commercialization. Waldman brings 35+ years of medical device commercial leadership, GPO and IDN experience, and sector expertise in patient safety, enteral feeding and neonatal nutrition. He previously grew a neonatal enteral portfolio from $39M to $70M in 3.5 years and will focus on expanding ENvue’s current presence in 38 hospitals and accelerating revenue across the company’s enteral platform.
ENvue Medical (NASDAQ: FEED) announced on January 14, 2026 the launch of over-the-counter ENFit syringes for enteral feeding and medication delivery, available without a prescription. The syringes will be sold in institutional and consumer-friendly packaging and are anticipated to appear at certain online retailers including Amazon and durable medical equipment suppliers. Offered in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, the devices comply with ISO 80369-3 and are designed for reuse for up to seven days or 20 uses, aiming to support continuity of care across clinical and home settings.
ENvue Medical (NASDAQ: FEED) launched a development and integration program to evaluate its clinically validated NanoVibronix vibration technology for reducing pain and discomfort from indwelling nasogastric (NG) tubes.
The program builds on previously published, peer‑reviewed research showing surface acoustic wave micro‑vibration can reduce friction at the tube–tissue interface. The effort is exploratory and focused on technical feasibility, clinical pathway assessment, and regulatory and quality considerations, and does not represent a commercial product launch or regulatory clearance.
ENvue Medical (NASDAQ: FEED) will ring the Nasdaq Opening Bell at Nasdaq MarketSite in Times Square on Wednesday, January 14, 2026. The ceremony, led by Doron Besser, MD, CEO, will include company leadership, directors, employees, and key stakeholders. The event is scheduled for 8:30 A.M. – 9:45 A.M. ET at 151 West 43rd Street and will be available via live webcast.
This public ceremonial event highlights the company’s focus on non-invasive enteral access and non-opioid pain management technologies and offers a visibility opportunity for investors and stakeholders to observe leadership remarks and company representation.
ENvue Medical (NASDAQ:NAOV) announced that the UroShield Kit was added to the UK NHS Drug Tariff Part IX on Dec 18, 2025, establishing a nationwide prescription reimbursement pathway.
The company also secured an initial purchase order from Peak Medical, a UK distributor, providing early commercial demand signal and near-term revenue visibility heading into 2026. The UroShield Actuator was previously included in the Drug Tariff in 2023, and UroShield is intended to reduce catheter-associated urinary tract infections by applying low-frequency ultrasonic energy to catheters.
ENvue Medical (NASDAQ: NAOV) announced that the UroShield® Kit was added to the UK NHS Drug Tariff Part IX on December 18, 2025, enabling nationwide prescription reimbursement across community and hospital settings.
ENvue also secured an initial purchase order from Peak Medical, its exclusive UK distributor, signaling early commercial demand and providing near-term revenue visibility heading into 2026. The UroShield system complements the previously listed UroShield Actuator (added to Drug Tariff Part IX in 2023) and targets reduction of catheter-associated urinary tract infections (CAUTIs) in long-term catheterized populations.
NanoVibronix (NASDAQ: NAOV) will change its corporate name to ENvue Medical and begin trading under the new ticker FEED at the open of market on December 12, 2025.
The rebrand aligns the company with its primary focus on the ENvue feeding-tube placement system and a strategy to scale hospital utilization, expand commercial reach, and build an enteral-feeding ecosystem. No action is required from current stockholders and the company’s common-stock CUSIP remains unchanged.
NanoVibronix (NASDAQ: NAOV) announced a strategic refocus around the ENvue feeding-tube placement system, which the company merged into NanoVibronix in early 2025 and says is 510(k) FDA-cleared and commercially available.
The company plans to rebrand as ENvue Medical with a new NASDAQ ticker, pursue hospital scaling and R&D (pediatric, imaging-overlay, vascular access, robotic guidance), and is exploring strategic alternatives for legacy NanoVibronix technologies. NanoVibronix reports a commercial base of 38 hospitals and cites a U.S. enteral-feeding market projected at ~$1.8 billion by 2030. The Board and leadership additions will be announced after the December 4, 2025 annual meeting.